After-Hours Stock Movers 12/08: (RH) (STRM) (APTX) Higher; (RLMD) (GME) (LCID) Lower (more...)

Lucid Group (LCID) Prices $1.75B Convertible Senior Notes Offering

Lucid Group, Inc. (Nasdaq: LCID) today announced the pricing of its offering of $1,750,000,000 aggregate principal amount of 1.25% convertible senior notes due 2026 (the "notes") in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The issuance and sale of the notes are scheduled to settle on or about December 14, 2021, subject to the satisfaction of customary closing conditions. Lucid also granted the initial purchasers of the notes an option, for settlement within a period of 13 days from,... More

fuboTV Inc (FUBO) Announces Multi-year Partnership with Professional Fighters League

The Professional Fighters League (PFL), the fastest growing and most innovative sports league, today announced an exclusive multi-year partnership for its new PFL Challenger Series with fuboTV Inc. (NYSE: FUBO), the leading sports-first live TV streaming platform.

The PFL Challenger Series debuts live on Friday, February 18, 2022, and will stream on consecutive Friday nights exclusively on fuboTV and its linear network, Fubo Sports Network, in February, March, and April.

The PFL Challenger Series takes the competition format familiar to MMA fans and makes it more exciting and modern with the innovative,... More

GameStop (GME) Losing 5% Following Miss on EPS, SEC Subpoena

GameStop (NYSE: GME) shares are trading over 5% lower in light pre-market trading, following 87c miss on EPS in the company's Q3 earning readout.

Additionally, the company disclosed a SEC subpoena concerning its trading activity.

Phreesia Inc. (PHR) PT Lowered to $65 at Needham & Company, But 'Buyers on Weakness'

Needham & Company analyst Ryan MacDonald lowered the price target on Phreesia Inc. (NYSE: PHR) to $65.00 (from $81.00) while maintaining a Buy rating.

The analyst commented, "We reiterate our Buy rating, while lowering our PT to $65, following the company's 3QF22 results in which revenue... More

Relmada Therapeutics (RLMD) Prices Upsized 8.82M Share Offering at $17/sh

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the pricing of an upsized underwritten public offering of 8,823,530 shares of its common stock at a public offering price of $17.00 per share. The gross proceeds to Relmada from the offering, before deducting underwriting discounts and commissions and other expenses payable by Relmada, are expected to be approximately $150 million. All of the shares in the offering are being sold by Relmada. The offering is expected to close on December 13, 2021, subject to customary closing conditions. In addition,... More